Paper39230804
Advancements and challenges: immunotherapy therapy in high-grade glioma - a meta-analysis of randomized clinical trials.
Palavani LB and 15 others. J Neurooncol, 2024. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Advancements and challenges: immunotherapy therapy in high-grade glioma - a meta-analysis of randomized clinical trials. Papers, record 39230804. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39230804
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Advancements and challenges: immunotherapy therapy in high-grade glioma - a meta-analysis of randomized clinical trials.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immunotherapy | Major topic |
| Glioma | Major topic |
| Brain Neoplasms | Major topic |
| Randomized Controlled Trials as Topic | Major topic |
| Humans | |
| Immune Checkpoint Inhibitors | |
| Cancer Vaccines | |
| Oncolytic Virotherapy |
Source PubMed
References62
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30159779 | Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial. | Cancer Immunol Immunother | 2018 | https://conductscience.org/library/papers/30159779 | PubMed |
| 2 | 26843484 | Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. | Neuro Oncol | 2016 | https://conductscience.org/library/papers/26843484 | PubMed |
| 3 | 37188783 | Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. | Nat Med | 2023 | https://conductscience.org/library/papers/37188783 | PubMed |
| 4 | 15930352 | Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. | Clin Cancer Res | 2005 | https://conductscience.org/library/papers/15930352 | PubMed |
| 5 | 37657463 | Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial. | Lancet Oncol | 2023 | https://conductscience.org/library/papers/37657463 | PubMed |
| 6 | 37004712 | Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial. | Lancet Child Adolesc Health | 2023 | https://conductscience.org/library/papers/37004712 | PubMed |
| 7 | 33109586 | Alpha-type-1 Polarized Dendritic Cell-based Vaccination in Newly Diagnosed High-grade Glioma: A Phase II Clinical Trial. | Anticancer Res | 2020 | https://conductscience.org/library/papers/33109586 | PubMed |
| 8 | 15328167 | Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. | Clin Cancer Res | 2004 | https://conductscience.org/library/papers/15328167 | PubMed |
| 9 | 34850166 | Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial. | Neuro Oncol | 2022 | https://conductscience.org/library/papers/34850166 | PubMed |
| 10 | 36517865 | Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment. | J Exp Clin Cancer Res | 2022 | https://conductscience.org/library/papers/36517865 | PubMed |
| 11 | 15256471 | Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. | Cancer Res | 2004 | https://conductscience.org/library/papers/15256471 | PubMed |
| 12 | 32477944 | Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series. | Front Oncol | 2020 | https://conductscience.org/library/papers/32477944 | PubMed |
| 13 | 23695293 | Drainage of cells and soluble antigen from the CNS to regional lymph nodes. | J Neuroimmune Pharmacol | 2013 | https://conductscience.org/library/papers/23695293 | PubMed |
| 14 | 26716896 | Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma. | Oncotarget | 2016 | https://conductscience.org/library/papers/26716896 | PubMed |
| 15 | 37196069 | Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results. | Oncologist | 2023 | https://conductscience.org/library/papers/37196069 | PubMed |
| 16 | 32750039 | Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme. | J Clin Invest | 2020 | https://conductscience.org/library/papers/32750039 | PubMed |
| 17 | 32669604 | Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis. | Sci Rep | 2020 | https://conductscience.org/library/papers/32669604 | PubMed |
| 18 | 36705923 | Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial. | JAMA Netw Open | 2023 | https://conductscience.org/library/papers/36705923 | PubMed |
| 19 | 2033653 | T-lymphocyte entry into the central nervous system. | J Neurosci Res | 1991 | https://conductscience.org/library/papers/2033653 | PubMed |
| 20 | 32437507 | Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/32437507 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41091250 | Premature mortality due to malignancies of the central nervous system in Japan: a nationwide descriptive analysis from 2000 to 2020. | J Neurooncol | 2025 | https://conductscience.org/library/papers/41091250 | PubMed |
| 39959084 | Crystallographic Structure and Antiglioma Potential of Centrolobium microchaete Seed Lectin. | ACS Omega | 2025 | https://conductscience.org/library/papers/39959084 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39230804
GET https://conductscience.org/api/papers/v1/39230804/references?page=2